Cleo Diagnostics reports its ovarian cancer blood tests superior to ultrasound

Nine moths after listing on the ASX, Cleo Diagnostics (ASX:COV) has made its first major biotech breakthrough.

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…